The 3-year results of the FinHer study indicated that survival free of distant disease was comparable among women with HER2+ cancer who received trastuzumab and those with HER2- cancer (HR 1.09, 95% CI 0.52–2.29, P = 0.82) [20]. The gene discussed is ERBB2; the disease is cancer.